Aa
Still UND 7977 & BMS 790052
Just got the call that 6 months post treatment I am still UND. My study will continue for another 6 months and then I will be followed for another 3 years by my Dr.
My new HepC Dr.'s office just called and I'm UND !!! Congrats to U.and Me and ALL OTHERS. Now I'm wondering from ALL, what are the withdrawall effects?
Margaret. If you're a geno 3, then the 7977+Riba will be better for you. Rather than 7977 and an NS5a. Have you ever tx before?
Jimeeboy...I thought you were on a the 12 week trial w/riba and started in March? I'm trying to compile data on people on these trials. Can you please fill me in and let me know your GT. Also, please confirm that you previously failed tx with SOC.
Thanks.
Thanks.
My thoughts exactly! I am GT3...but would gladly take my chances!
Sounds like you are CURED!!!!!! YIPPPPPEEEEEEEE!!!!!
Sounds like you are CURED!!!!!! YIPPPPPEEEEEEEE!!!!!
Holy ****! 100% of G1 participants were cured. That would be me. I'm also taking ribiviran. 4 weeks left then I'm done. Very encouraging.
The results are IN - 24 weeks AFTER End of Treatment!
Daclatasvir and GS-7977
By Sean R. Hosein
From Canadian AIDS Treatment Information Exchange
July 2012
Daclatasvir was the first oral HCV NS5A inhibitor to be developed. GS-7977 is a nuke with activity against NS5B. Both drugs have powerful anti-HCV activity when used separately. In study AI444-040, researchers in the U.S. studied different combinations of both drugs in a randomized clinical trial with HCV-positive people infected with the following genotypes:
•genotype 1a, 1b, 2, and 3
Researchers recruited participants and assigned them to the following six groups:
Group A
•15 participants with genotypes 1a and 1b: all received GS-7977 monotherapy for seven days after which daclatasvir was added; dual therapy continued for 23 weeks
Group B
•16 participants with genotypes 2 and 3: all received GS-7977 monotherapy for seven days after which daclatasvir 60 mg once daily was added; dual therapy continued for 23 weeks
AdvertisementGroup C
•14 participants with genotypes 1a and 1b: all received immediate dual therapy with daclatasvir and GS-7977, both for 24 weeks
Group D
•14 participants with genotypes 2 and 3: all received immediate dual therapy with daclatasvir and GS-7977, both for 24 weeks
Group E
•15 participants with genotypes 1a and 1b: all received triple therapy with daclatasvir, GS-7977 and ribavirin (dosed between 1,000 and 1,200 mg/day), all for 24 weeks
Group F
•14 participants with genotypes 2 and 3: all received triple therapy with daclatasvir, GS-7977 and ribavirin at 800 mg/day, all for 24 weeks
All participants were monitored for an additional 24 weeks once they stopped experimental therapy.
The average profile of participants upon entering the study was as follows:
•age -- 53 years
•50% men, 50% women
•HCV viral load -- 4 million IU/ml
Results
The decline in HCV levels was faster among participants who received combination therapy immediately rather than delaying combination therapy. Viral suppression was similar in groups C, D, E and F.
Adding ribavirin did not accelerate the decline of HCV viral load.
After four weeks of experimental therapy, 100% of genotype 1 participants had undetectable levels of HCV. The equivalent figure for genotype 2 and3 participants was 91%.
Two participants stopped returning to the study clinic for unknown reason(s). Their last blood samples at weeks 12 and 24 respectively were undetectable.
One participant had his HCV levels rise after first suppressing them.
Another participant (in group B) had his HCV levels rise but doctors enhanced his therapy with interferon + ribavirin and his viral load returned to suppressed levels.
Safety
No deaths occurred.
Two participants left the study because of adverse events: one case of stroke (group C) and one case of fibromyalgia (group F). Researchers considered both incidents to be unrelated to the study.
Serious adverse events occurred in 10 patients, but only three cases were judged to be related to the study medicines and all occurred when patients accidentally took extra doses of daclastavir or GS-7977.
Adverse events in the study that were not related to the experimental treatments were as follows:
•anxiety -- 2 participants
•fracture -- 1 participant
•lung pain -- 1 participant
•intestinal inflammation -- 1 participant
•kidney failure -- 1 participant
No cases of severely elevated liver enzymes occurred.
The most common laboratory abnormality was anemia and this occurred in participants who received ribavirin.
In summary, the all-oral regimen of two new drugs without ribavirin cured 100% of genotype 1 participants and at least 90% of genotype 2 and 3 participants.
These very promising findings require confirmation in a larger study.
Reference
Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV genotype 1,2 or 3. In: Program and abstracts of the 47th annual meeting of the European Association for the Study of the Liver, 18-22 April 2012, Barcelona, Spain
"These very promising findings require confirmation in a larger study"...
This "larger study" is NOT going to happen UNLESS we take ACTION!!!
Post this everywhere! We want this CURE NOW!
http://www.thebodypro.com/content/68441/daclatasvir-and-gs-7977.html
Daclatasvir and GS-7977
By Sean R. Hosein
From Canadian AIDS Treatment Information Exchange
July 2012
Daclatasvir was the first oral HCV NS5A inhibitor to be developed. GS-7977 is a nuke with activity against NS5B. Both drugs have powerful anti-HCV activity when used separately. In study AI444-040, researchers in the U.S. studied different combinations of both drugs in a randomized clinical trial with HCV-positive people infected with the following genotypes:
•genotype 1a, 1b, 2, and 3
Researchers recruited participants and assigned them to the following six groups:
Group A
•15 participants with genotypes 1a and 1b: all received GS-7977 monotherapy for seven days after which daclatasvir was added; dual therapy continued for 23 weeks
Group B
•16 participants with genotypes 2 and 3: all received GS-7977 monotherapy for seven days after which daclatasvir 60 mg once daily was added; dual therapy continued for 23 weeks
AdvertisementGroup C
•14 participants with genotypes 1a and 1b: all received immediate dual therapy with daclatasvir and GS-7977, both for 24 weeks
Group D
•14 participants with genotypes 2 and 3: all received immediate dual therapy with daclatasvir and GS-7977, both for 24 weeks
Group E
•15 participants with genotypes 1a and 1b: all received triple therapy with daclatasvir, GS-7977 and ribavirin (dosed between 1,000 and 1,200 mg/day), all for 24 weeks
Group F
•14 participants with genotypes 2 and 3: all received triple therapy with daclatasvir, GS-7977 and ribavirin at 800 mg/day, all for 24 weeks
All participants were monitored for an additional 24 weeks once they stopped experimental therapy.
The average profile of participants upon entering the study was as follows:
•age -- 53 years
•50% men, 50% women
•HCV viral load -- 4 million IU/ml
Results
The decline in HCV levels was faster among participants who received combination therapy immediately rather than delaying combination therapy. Viral suppression was similar in groups C, D, E and F.
Adding ribavirin did not accelerate the decline of HCV viral load.
After four weeks of experimental therapy, 100% of genotype 1 participants had undetectable levels of HCV. The equivalent figure for genotype 2 and3 participants was 91%.
Two participants stopped returning to the study clinic for unknown reason(s). Their last blood samples at weeks 12 and 24 respectively were undetectable.
One participant had his HCV levels rise after first suppressing them.
Another participant (in group B) had his HCV levels rise but doctors enhanced his therapy with interferon + ribavirin and his viral load returned to suppressed levels.
Safety
No deaths occurred.
Two participants left the study because of adverse events: one case of stroke (group C) and one case of fibromyalgia (group F). Researchers considered both incidents to be unrelated to the study.
Serious adverse events occurred in 10 patients, but only three cases were judged to be related to the study medicines and all occurred when patients accidentally took extra doses of daclastavir or GS-7977.
Adverse events in the study that were not related to the experimental treatments were as follows:
•anxiety -- 2 participants
•fracture -- 1 participant
•lung pain -- 1 participant
•intestinal inflammation -- 1 participant
•kidney failure -- 1 participant
No cases of severely elevated liver enzymes occurred.
The most common laboratory abnormality was anemia and this occurred in participants who received ribavirin.
In summary, the all-oral regimen of two new drugs without ribavirin cured 100% of genotype 1 participants and at least 90% of genotype 2 and 3 participants.
These very promising findings require confirmation in a larger study.
Reference
Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV genotype 1,2 or 3. In: Program and abstracts of the 47th annual meeting of the European Association for the Study of the Liver, 18-22 April 2012, Barcelona, Spain
"These very promising findings require confirmation in a larger study"...
This "larger study" is NOT going to happen UNLESS we take ACTION!!!
Post this everywhere! We want this CURE NOW!
http://www.thebodypro.com/content/68441/daclatasvir-and-gs-7977.html
Great to hear this! I know a few people that wont treat because of the interferon. Congratulations!
Please sign and share the petition and keep spreading the word....the more people in the world who know about these successful trials, the better our chance of getting them to move forward!
http://www.change.org/petitions/gilead-sciences-please-collaborate-with-bristol-myers-for-the-cure-for-hepatitis-c-now
http://www.change.org/petitions/gilead-sciences-please-collaborate-with-bristol-myers-for-the-cure-for-hepatitis-c-now
That is amazing, you are not "gonnabe" you ARE Hep C Free...woot!
This gives hope to so many people : )
I hope and pray for this Tx to be approved ASAP!
This gives hope to so many people : )
I hope and pray for this Tx to be approved ASAP!
Congrats !!! That's huge---ALL ORAL SVR--really happy for you !! Hope the results were as good for the others as it was for you---making for a non riba / interferon treatment (no sides) in the near future.
Great news. We hope to start following in your footsteps in September. It must feel great.
WOW - and no riba and no side effects. I am impressed. congratulation and hooray for a wave of the future
Have an Answer?
You are reading content posted in the Hepatitis Social Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
